Barclays
SNNA

Barclays’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Barclays’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-65
Closed – – 6752
2019
Q4 		$0 Hold
65
– – ﹤0.01% 7141
2019
Q3 		$0 Sell
65
-22,307
-100% -$15.1K ﹤0.01% 7407
2019
Q2 		$20K Buy
22,372
+17,763
+385% +$27.8K ﹤0.01% 6414
2019
Q1 		$11K Buy
4,609
+4,544
+6,991% +$12.3K ﹤0.01% 6540
2018
Q4 		$0 Sell
65
-5,782
-99% -$51K ﹤0.01% 7636
2018
Q3 		$87K Buy
5,847
+4,720
+419% +$75K ﹤0.01% 5693
2018
Q2 		$17K Sell
1,127
-2,207
-66% -$37.5K ﹤0.01% 6292
2018
Q1 		$63K Buy
3,334
+2,536
+318% +$44.3K ﹤0.01% 5728
2017
Q4 		$14K Sell
798
-6,470
-89% -$137K ﹤0.01% 6434
2017
Q3 		$162K Buy
+7,268
New +$160K ﹤0.01% 4602

Barclays's SNNA Position: Q1 2020 in Review

Barclays sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2020, closing a stake of 65 shares.

Barclays first reported a position in SNNA in Q3 2017 and held it in 10 quarters. The position peaked at $162K in Q3 2017. 1 fund tracked by Wall St. Rank holds SNNA as of Q1 2020.

  • Barclays reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 65 Sienna Biopharmaceuticals, Inc. shares in Q1 2020.
  • Barclays first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 10 quarters.
  • Barclays's Sienna Biopharmaceuticals, Inc. position peaked at $162K in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.